Logo

CELZ

Creative Medical Technology Holdings, Inc.

CELZ

Creative Medical Technology Holdings, Inc. • NASDAQ
$2.69 ▲ 0.75% (+0.02)
Market Cap $6.94 M
52w High $6.90
52w Low $1.69
Dividend Yield 0%
P/E -0.95
Volume 11.78K
Outstanding Shares 2.58M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.273M ▲ $-1.236M ▼ 0% $-0.48 $-1.205M ▼
Q2-2025 $0 ▼ $1.233M ▼ $-1.233M ▲ 0% ▲ $-0.48 ▲ $-1.203M ▲
Q1-2025 $3K $1.662M ▼ $-1.638M ▲ -54.603K% ▲ $-0.83 ▲ $-1.63M ▲
Q4-2024 $3K ▲ $1.888M ▲ $-1.854M ▼ -61.802K% ▼ $-1.12 ▼ $-1.945M ▼
Q3-2024 $0 $1.08M $-1.04M 0% $-0.75 $-1.011M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.376M ▼ $5.853M ▼ $261.353K ▼ $5.592M ▼
Q2-2025 $6.544M ▼ $7.105M ▼ $277.644K ▼ $6.828M ▼
Q1-2025 $7.703M ▲ $8.347M ▲ $286.387K ▼ $8.061M ▲
Q4-2024 $5.94M ▼ $6.669M ▼ $327.644K ▼ $6.341M ▼
Q3-2024 $6.26M $6.888M $330.908K $6.557M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.236M ▼ $-1.169M ▼ $0 $0 $-1.169M ▼ $-1.169M ▼
Q2-2025 $-1.233M ▲ $-1.159M ▲ $0 $0 ▼ $-1.159M ▼ $-1.159M ▲
Q1-2025 $-1.638M ▲ $-1.592M ▲ $0 $3.354M ▲ $1.762M ▲ $-1.592M ▲
Q4-2024 $-1.854M ▼ $-1.95M ▼ $0 ▲ $1.629M ▲ $-320.036K ▲ $-1.95M ▼
Q3-2024 $-1.04M $-985.588K $-200K $-25.45K $-1.211M $-985.59K

Five-Year Company Overview

Income Statement

Income Statement CELZ is still a pure development-stage biotech company with no meaningful revenue. The income statement is driven almost entirely by research and administrative spending, which results in continuing losses each year. Those losses are relatively small in absolute dollar terms but large when compared with the tiny size of the company. The dramatic swings in reported earnings per share mainly reflect past reverse stock splits and capital structure changes rather than shifts in the underlying business. Overall, the income statement shows a company still firmly in the “build and test” phase, not yet in the “sell and scale” phase.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small amount of total assets and cash, and no reported debt. Equity is positive but thin, which is typical for a micro‑cap clinical‑stage biotech that has funded itself primarily through issuing stock. The absence of debt reduces interest burden and financial strain, but the limited asset and cash base also means the company has a short financial runway and remains highly dependent on future capital raises. Past reverse splits highlight how much the company has already relied on the equity markets to fund operations.

Cash Flow

Cash Flow Cash flows reflect a straightforward story: money is being used to fund operations and development, with no offsetting cash coming in from product sales. Operating cash flow is consistently negative, and free cash flow is negative as well, although capital spending needs appear modest. This profile is common for early-stage biotech, but it means that sustaining the business and advancing trials will likely require periodic new financing until a commercial product or significant partnership is achieved.

Competitive Edge

Competitive Edge CELZ operates in a very competitive part of healthcare—regenerative medicine and cell therapy—where many better‑funded players are also active. Its potential edge comes from a diversified platform approach (AlloStem, ImmCelz, iPScelz), a growing patent portfolio, and some early regulatory advantages such as fast‑track and orphan designations in certain indications. If its therapies show strong clinical data, these factors could provide a defensible niche. Until then, the company competes mainly on scientific promise rather than on market share, brand, or commercial scale.

Innovation and R&D

Innovation and R&D Innovation is the clear focus and main asset of CELZ. The company is working across multiple cell‑based platforms, including off‑the‑shelf donor cells, personalized immune cell reprogramming, and AI‑assisted induced pluripotent stem cell technologies. Its pipeline targets difficult, high‑value conditions such as chronic back pain, type 1 diabetes, and sexual dysfunction. Partnerships around AI and a sizable patent estate support the idea of a strong R&D engine. However, most programs are still in early to mid‑stage trials, so scientific and regulatory risk remains high, and timelines are long and uncertain.

Summary

CELZ is a tiny, clinical‑stage biotech company whose story is almost entirely about future potential rather than current financial performance. The financial statements show no revenue, ongoing operating losses, and a very small but debt‑free balance sheet funded largely through equity issuance. Cash burn is steady and will likely require additional capital over time. On the strategic side, the company’s value proposition rests on a diversified set of regenerative medicine platforms, a growing intellectual property portfolio, and early regulatory designations in areas of unmet medical need. The opportunity is meaningful if its therapies succeed, but the company faces the usual challenges of small biotech: scientific, regulatory, execution, and financing risks, all before any commercial scale is proven.

NEWS

October 30, 2025 · 9:15 AM UTC

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Read more

October 29, 2025 · 9:00 AM UTC

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

Read more

October 27, 2025 · 8:15 AM UTC

Creative Medical Technology Holdings Issues Letter to Shareholders

Read more

October 7, 2025 · 9:15 AM UTC

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Read more